Results 1 to 10 of about 16,374 (168)

Combined detection of urinary biomarkers noninvasively predicts extent of renal injury in patients with early diabetic kidney disease with kidney qi deficiency syndrome: A retrospective investigation

The Anatomical Record, Volume 306, Issue 12, Page 2945-2957, December 2023., 2023
Abstract Incipient diagnosis and noninvasive forecasts using urinary biomarkers are important for preventing diabetic kidney disease (DKD) progression, but they are also controversial. Previous studies have shown a potential relationship between urinary tubular biomarkers (UTBs) and traditional Chinese medicine (TCM) syndrome in patients with DKD. Thus,
Wei Wu, Xian‐Jie Meng, Bing‐Ying Wan, Qi‐Jun Fang, Ying‐Lu Liu, Jie Wang, Yan Fu, Can‐Can Yuan, Mei‐Zi Wang, Fee‐Lan Chong, Yi‐Gang Wan, Shan‐Mei Shen   +11 more
wiley   +1 more source

Rationale and design for the Blood Pressure Control Target in Diabetes (BPROAD) study 糖尿病血压控制目标(BPROAD)研究的原理和设计

Journal of Diabetes, Volume 15, Issue 12, Page 1029-1040, December 2023., 2023
Highlights The Blood Pressure Control Target in Diabetes (BPROAD) study is a multicenter, randomized controlled trial conducted in mainland China to test the hypothesis of whether intensive blood pressure (BP) management (systolic BP <120 mm Hg) has additional benefits over standard BP management (systolic BP <140 mm Hg) over a follow‐up period of up ...
The BPROAD Study Group, Guang Ning, Jiang He, Weiqing Wang, Yufang Bi, Dalong Zhu, Jiguang Wang, Shengdi Chen, Yu Xu, BPROAD coordinating team at Ruijin Hospital, Lawrence J. Appel, William C. Cushman, Vivian A. Fonseca, Jeff D. Williamson, David M. Reboussin, Yaling Han, Hongbing Shen, Minghui Zhao, Hui Wang   +18 more
wiley   +1 more source

Blood pressure targets for prevention of cognitive decline in patients with diabetes and hypertension: Design of the Blood Pressure Control Target in Diabetes (BPROAD) Cognitive Study 高血压目标对于预防糖尿病和高血压患者的认知下降:BPROAD认知研究的设计

Journal of Diabetes, Volume 15, Issue 12, Page 1041-1047, December 2023., 2023
Highlights The optimal blood pressure (BP) target in patients with type 2 diabetes mellitus (T2DM) for the management of cognitive decline remains unknown. The Blood Pressure Control Target in Diabetes (BPROAD) Cognitive Study was designed to determine whether intensive BP treatment (systolic BP <120 mm Hg) reduces risk of dementia and mild cognitive ...
The BPROAD Study Group, Guang Ning, Jiang He, Weiqing Wang, Yufang Bi, Dalong Zhu, Jiguang Wang, Shengdi Chen, Yu Xu, BPROAD coordinating team at Ruijin Hospital, Lawrence J. Appel, William C. Cushman, Vivian A. Fonseca, Jeff D. Williamson, David M. Reboussin, Yaling Han, Hongbing Shen, Minghui Zhao, Hui Wang   +18 more
wiley   +1 more source

Patient experiences of continuous glucose monitoring and sensor‐augmented insulin pump therapy for diabetes: A systematic review of qualitative studies 糖尿病患者接受连续血糖监测和传感器增强胰岛素泵治疗的体验:对定性研究的系统综述

Journal of Diabetes, Volume 15, Issue 12, Page 1048-1069, December 2023., 2023
Highlights We identified that CGM can increase motivation for self‐management and confidence in treatments. A supportive treating team may help to reduce the practical and psychological burden in patients with type 1 and type 2 diabetes. Abstract Aims Blood glucose control is central to the management of diabetes, and continuous glucose monitoring (CGM)
Patrizia Natale, Sharon Chen, Clara K. Chow, Ngai Wah Cheung, David Martinez‐Martin, Corinne Caillaud, Nicole Scholes‐Robertson, Ayano Kelly, Jonathan C. Craig, Giovanni Strippoli, Allison Jaure   +10 more
wiley   +1 more source

Early weight gain after diagnosis may have an impact on remission status in children with new‐onset type 1 diabetes mellitus 儿童新发1型糖尿病诊断后早期体重增加可能对缓解状态产生影响

Journal of Diabetes, Volume 15, Issue 12, Page 1011-1019, December 2023., 2023
Highlights Weight gain with insulin therapy in the early period may be negatively related to the occurrence and duration of remission by altering insulin sensitivity. Interventions to prevent rapid weight gain and conserve insulin sensitivity in the early stages of type 1 diabetes mellitus may be beneficial for the development and maintenance of ...
Dicle Canoruc Emet, Hande Nur Karavar, Onur Gozmen, Arife Aslan Agyar, Yağmur Ünsal, Merve Canturk, Pınar Cengiz, Dogus Vuralli, Z. Alev Ozon, E. Nazlı Gonc   +9 more
wiley   +1 more source

Decreased in n‐3 DHA enriched triacylglycerol in small extracellular vesicles of diabetic patients with cardiac dysfunction 糖尿病合并心脏功能障碍患者细胞外小囊泡中n‐3 DHA 富集的三酰甘油减少

Journal of Diabetes, Volume 15, Issue 12, Page 1070-1080, December 2023., 2023
Highlights Lipid profiles of small extracellular vesicles (sEVs) in patients with diabetes or diabetic cardiovascular disease are rarely reported. n‐3 docosahexaenoic acid (DHA)‐enriched triacylglycerol (TG) was found to decrease in sEVs from serum of patients with diabetic cardiovascular disease (DM‐CAD).
Wei Ding, Xuejuan Zhang, Dandan Xiao, Wenguang Chang   +3 more
wiley   +1 more source

Fatty acid β‐oxidation and mitochondrial fusion are involved in cardiac microvascular endothelial cell protection induced by glucagon receptor antagonism in diabetic mice 脂肪酸β‐氧化和线粒体融合参与胰高血糖素受体拮抗剂对糖尿病小鼠心脏微血管内皮细胞的保护作用

Journal of Diabetes, Volume 15, Issue 12, Page 1081-1094, December 2023., 2023
Highlights Glucagon receptor (GCGR) monoclonal antibody (mAb) improves cardiac function and attenuates microvascular damage in db/db mice. GCGR mAb ameliorates the oxidative stress of cardiac microvascular endothelial cells in diabetic mice. GCGR mAb counteracts the diabetes‐induced upregulation of carnitine palmitoyltransferase 1B, optic atrophy type ...
Peng Wang, Rui Wei, Xiaona Cui, Zongzhe Jiang, Jin Yang, Lingyun Zu, Tianpei Hong   +6 more
wiley   +1 more source

A network meta‐analysis of association between cardiometabolic risk factors and COVID‐19 outcome severity 心血管代谢危险因素与COVID‐19严重程度关联的网络荟萃分析

Journal of Diabetes, Volume 15, Issue 11, Page 968-977, November 2023., 2023
Highlights Among 301 studies, diabetes mellitus was the most studied cardiometabolic risk factor. In the network meta‐analysis, cerebrovascular disease had the highest impact (relative risk [RR] 1.69; 95% CI, 1.65–1.73) on COVID‐19 outcomes compared to other cardiometabolic risk factors.
Alina Binbin Li, Bo Yang, Yufei Li, Rachel Huynh, Samuel Shim, Kenneth Lo, Jie Li, Andrew Zullo, Wen‐Chih Wu, Simin Liu   +9 more
wiley   +1 more source

Effect of dipeptidyl peptidase‐4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus DPP‐4抑制剂对接受胰岛素治疗的2型糖尿病患者冠状动脉疾病进展的影响

Journal of Diabetes, Volume 15, Issue 11, Page 944-954, November 2023., 2023
Highlights Preclinical data showed that dipeptidyl peptidase‐4 inhibitors (DPP‐4is) may prevent insulin‐induced atherosclerosis. In patients treated with insulin for type 2 diabetes who underwent ≥2 serial coronary computed tomography angiographies(CCTA), a new obstructive coronary artery disease (OCAD) was less developed on the follow‐up CCTA in those
Young Choi, Seung‐Hyun Ko, Kiyuk Chang, Ki Dong Yoo, Sang‐Hyun Ihm   +4 more
wiley   +1 more source